Glucagon-like Peptide-1 Receptor Agonists in Neoplastic Diseases

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Oct 7

PMID 39371922

Authors

Lisan Ji

Xianzhen He

Xinwen Min

Handong Yang

Wenwen Wu

Hao Xu

Jun Chen

Aihua Mei

Affiliations

Soon will be listed here.

Abstract

Glucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing weight, and lowering blood lipids. It has also been shown that it can influence the proliferation and survival of cells and has a certain effect on the prognosis of some neoplastic diseases. In this study, the potential effects of GLP-1RAs on the occurrence and development of tumors were reviewed to provide new ideas for the prevention and treatment of tumors in patients.

Citing Articles

Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway.

Wang C, Wu Z, Zhou J, Cheng B, Huang Y J Cancer Res Clin Oncol. 2025; 151(3):103.

PMID: 40055197 PMC: 11889073. DOI: 10.1007/s00432-025-06154-5.

References

Lee Y, Lee C, Choung J, Jung H, Jun H . Glucagon-Like Peptide 1 Increases β-Cell Regeneration by Promoting α- to β-Cell Transdifferentiation. Diabetes. 2018; 67(12):2601-2614. DOI: 10.2337/db18-0155. View

Kim J, Lee S, Jo K, Song D, Lim D, Park K . Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. Life Sci. 2013; 92(10):533-40. DOI: 10.1016/j.lfs.2013.01.001. View

Wettergren A, Wojdemann M, Holst J . Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol. 1998; 275(5):G984-92. DOI: 10.1152/ajpgi.1998.275.5.G984. View

Dal Molin M, Kim H, Blackford A, Sharma R, Goggins M . Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues. Pancreas. 2015; 45(4):613-9. PMC: 4783303. DOI: 10.1097/MPA.0000000000000521. View

Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T . Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Hepatology. 2018; 69(6):2414-2426. PMC: 6594101. DOI: 10.1002/hep.30320. View

Holz G . Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes. 2003; 53(1):5-13. PMC: 3012130. DOI: 10.2337/diabetes.53.1.5. View

Barritt 4th A, Marshman E, Noureddin M . Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. Aliment Pharmacol Ther. 2022; 55(8):944-959. PMC: 9310586. DOI: 10.1111/apt.16794. View

Gilbert M, Pratley R . GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Front Endocrinol (Lausanne). 2020; 11:178. PMC: 7145895. DOI: 10.3389/fendo.2020.00178. View

Manasanch E, Orlowski R . Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017; 14(7):417-433. PMC: 5828026. DOI: 10.1038/nrclinonc.2016.206. View

10.

Baggio L, Yusta B, Mulvihill E, Cao X, Streutker C, Butany J . GLP-1 Receptor Expression Within the Human Heart. Endocrinology. 2018; 159(4):1570-1584. PMC: 5939638. DOI: 10.1210/en.2018-00004. View

11.

Bobustuc G, Kassam A, Rovin R, Jeudy S, Smith J, Isley B . MGMT inhibition in ER positive breast cancer leads to CDC2, TOP2A, AURKB, CDC20, KIF20A, Cyclin A2, Cyclin B2, Cyclin D1, ERα and Survivin inhibition and enhances response to temozolomide. Oncotarget. 2018; 9(51):29727-29742. PMC: 6049872. DOI: 10.18632/oncotarget.25696. View

12.

Zhao H, Wang L, Wei R, Xiu D, Tao M, Ke J . Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway. Diabetes Obes Metab. 2014; 16(9):850-60. DOI: 10.1111/dom.12291. View

13.

Wenjing H, Shuang Y, Weisong L, Haipeng X . Exendin-4 does not modify growth or apoptosis of human colon cancer cells. Endocr Res. 2017; 42(3):209-218. DOI: 10.1080/07435800.2017.1292525. View

14.

Bunemann M, Gerhardstein B, Gao T, Hosey M . Functional regulation of L-type calcium channels via protein kinase A-mediated phosphorylation of the beta(2) subunit. J Biol Chem. 1999; 274(48):33851-4. DOI: 10.1074/jbc.274.48.33851. View

15.

Singh S, Chang H, Richards T, Weiner J, Clark J, Segal J . Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013; 173(7):534-9. DOI: 10.1001/jamainternmed.2013.2720. View

16.

Burmeister M, Ferre T, Ayala J, King E, Holt R, Ayala J . Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice. Am J Physiol Endocrinol Metab. 2011; 302(3):E334-43. DOI: 10.1152/ajpendo.00409.2011. View

17.

Nauck M, Quast D, Wefers J, Meier J . GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2020; 46:101102. PMC: 8085572. DOI: 10.1016/j.molmet.2020.101102. View

18.

Knapen L, van Dalem J, Keulemans Y, Van Erp N, Bazelier M, De Bruin M . Use of incretin agents and risk of pancreatic cancer: a population-based cohort study. Diabetes Obes Metab. 2015; 18(3):258-65. DOI: 10.1111/dom.12605. View

19.

Lee P, Papachristou G . New insights into acute pancreatitis. Nat Rev Gastroenterol Hepatol. 2019; 16(8):479-496. DOI: 10.1038/s41575-019-0158-2. View

20.

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Furtado R . Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019; 139(17):2022-2031. DOI: 10.1161/CIRCULATIONAHA.118.038868. View